PSMA-PET Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial.

Purpose: To assess the safety of using combined Gallium68-prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/computed tomography (CT) (Ga-PSMA-PET/CT) and multiparametric magnetic resonance imaging (mpMRI) for planning dominant intraprostatic lesion (DIL) boost in prostate stereotactic radiation therapy (SBRT) for dose escalation (PROBE).

Methods And Materials: Patients with intermediate- or high-risk prostate adenocarcinoma with DIL identified on mpMRI and Ga-PSMA-PET/CT and suitable for SBRT were enrolled in this phase 2 trial. Ga-PSMA-PET/CT was fused with mpMRI for gross tumor volume (GTV) delineation.

Online Adaptive Radiation Therapy for Bladder Preservation: Transitioning to Hypofractionation.

Purpose: To present the clinical experience of bladder preservation with adaptive radiation therapy (ART) in conventionally fractionated radiation therapy (ConvRT) and discuss the challenges in transitioning to hypofractionated radiation therapy (HypoRT).

Methods And Materials: Consecutive patients from a prospectively maintained institutional database with histologically proven urothelial carcinoma, staged T1 to T4, N0 to N3, M0, treated with curative intent chemoradiation therapy from January 2014 to December 2023 were included. Patients from 2014 were treated with a dose of 64 Gy/32# to the bladder and 55 Gy/32# to the pelvis.

Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial.

Purpose: To report toxicity from the multicenter phase III randomized trial of Bladder Adjuvant Radiation Therapy (BART) after radical cystectomy and chemotherapy in high-risk muscle-invasive bladder cancer (MIBC).

Methods And Materials: Patients with nonmetastatic urothelial MIBC with ≥1 high-risk feature after radical cystectomy- pT3-4, pN1-3, nodal yield <10, positive margin, or ≥cT3 downstaged with neoadjuvant chemotherapy- were randomized 1:1 to observation (Obs) or adjuvant radiation therapy (RT) at 4 centers, stratified by pN stage (N0, N+) and chemotherapy (neoadjuvant, adjuvant, none). Stoma-sparing image guided intensity modulated RT 50.

Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate.

Purpose: To study the late urinary toxicity in patients with prostate cancer with prior transurethral resection of prostate (TURP) and treated with hypofractionated prostate radiation therapy.

Methods And Materials: Patients diagnosed with prostate cancer, with a prior TURP, and treated with moderate or extreme hypofractionated intensity-modulated radiation therapy (moderate hypofractionated radiation therapy [MHRT], stereotactic body radiation therapy [SBRT]), were included in this study. Severity and duration of urinary symptoms observed during serial follow-up after at least 3 months from radiation therapy were graded per National Cancer Institute Common Terminology Criteria for Adverse Events v5.

Late Urinary Toxicity and Quality of Life With Pelvic Radiation Therapy for High-Risk Prostate Cancer: Dose-Effect Relations in the POP-RT Randomized Phase 3 Trial.

Purpose: The POP-RT phase 3 randomized trial showed improved biochemical failure-free survival and metastasis-free survival with whole pelvic radiation therapy versus prostate-only radiation therapy for high and very high-risk prostate cancer, albeit with worse RTOG late urinary toxicity. We report updated late urinary adverse effects and bladder dose-effect relations within this trial.

Methods And Materials: Late urinary toxicity and the cumulative severity of each symptom during the follow-up period were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.